Cytokine-based immunotherapy agents such IFN-α, emerges as a standard care for the advanced RCC treatment; however, several studies showed that these cytokine stimulators either or in combination, failed to improve the disease-free survival or overall survival. Here, IFNA1 is linked to renal cell carcinoma.